Landmark, pivotal Phase IIb/III trial of biotoxin for cancer pain begins
A multicentre, randomized, double-blind and placebo-controlled study is underway to evaluate the efficacy and safety of Tectin in moderate to severe inadequately controlled cancer-related pain. The trial has shown promising results, with almost three-quarters of patients experiencing a clinically meaningful analgesic response.